he end-user customer. Cadence recognized this deferred revenue during the period as it determined it had obtained sufficient product return history as of January 1, 2013, to reasonably estimate future wholesaler returns. As a result, the company recorded a one-time adjustment during the three months ended March 31, 2013, to recognize deferred revenue on previously shipped product, resulting in additional net revenue of $2.6 million and cost of sales of $0.9 million, for a net gross margin impact of $1.7 million.
For the three months ended March 31, 2013, Cadence reported a net loss of $1.4 million, or $0.02 per share, compared to a net loss of $22.7 million, or $0.27 per share, for the comparable period in 2012. Included in the company's net loss for the three months ended March 31, 2013, was a gain of $7.7 million Cadence recorded on the waiver, termination and sale of its Incline assets in January 2013, for which the company received cash payments totaling $14.6 million. Excluding the $7.7 million gain from the Incline transaction, and the $1.7 million gross margin impact from the change in the company's revenue recognition accounting estimate, Cadence's net loss for the three months ended March 31, 2013, was $10.8 million, or $0.13 per share.
Gross margin for the three months ended March 31, 2013, was 65%, compared to 47% for the comparable period in 2012. The increase in margin was primarily a result of higher freight costs incurred during the first quarter of 2012 that were not incurred in 2013, the impact of price increases implemented in July 2012 and January 2013, and a one-time credit of $0.3 million recorded during the three months ended March 31, 2013, in connection with the termination of the company's supply agreement with Baxter. Operating expenses, including patent amortization, decreased $2.0 million for the three months ended March 31, 2013, to $23.4 million, from $25.4 million for the same period in 2012. This decrease in
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results2
. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 20123
. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 20124
. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.5
. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer6
. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones7
. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer8
. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ9
. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 201710
. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-9911
. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results